Mostrar el registro sencillo del ítem

dc.contributor.author
Gagliardino, Juan Jose  
dc.contributor.author
Elgart, Jorge Federico  
dc.contributor.author
Forti, Luján  
dc.contributor.author
Querzoli, Ivanna  
dc.contributor.author
Chantelot, Jean Marc  
dc.date.available
2021-01-12T13:53:57Z  
dc.date.issued
2019-07  
dc.identifier.citation
Gagliardino, Juan Jose; Elgart, Jorge Federico; Forti, Luján; Querzoli, Ivanna; Chantelot, Jean Marc; Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina; Elsevier Ireland; Diabetes Research and Clinical Practice; 153; 7-2019; 86-92  
dc.identifier.issn
0168-8227  
dc.identifier.uri
http://hdl.handle.net/11336/122469  
dc.description.abstract
Aim To assess prescription patterns for treatment of type 2 diabetes (T2D) and their outcomes in the IDMPS survey in Argentina. Methods Data from 2551 people with T2D recruited from 210 physicians participating in IDMPS surveys in Argentina (2006 to 2012 waves) were recorded, including medical history, medications, glycemic control, blood pressure, and lipid status. Results Most people were treated with oral glucose-lowering drugs (OGLDs) (65%), followed by combinations of these drugs plus insulin (22%) and only insulin (13%). These percentages varied according to T2D duration, the frequency of OGLDs decreasing while contrastingly and only insulin increasing (under 5 years versus over 10 years of disease duration, respectively). Average systolic blood pressure (SBP), HbA1c and LDL-c were significantly higher in patients treated with insulin either alone or associated with OGLDs. The percentage of people at target values for these parameters was also lower in these two groups. The percentage of people that reached simultaneous goal treatment values for BP, HbA1c and LDL-c levels was markedly low. Conclusion Prescription patterns for treatment of T2D follows a chronological trend and the percentage of people at goal values (HbA1c, BP and LDL-c values) was significantly lower in people receiving insulin. These data must be carefully considered by health and academic authorities in order to implement effective strategies to modify this situation.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Elsevier Ireland  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
COMBINED TREATMENT GOALS  
dc.subject
HBA1C AND INSULIN TREATMENT  
dc.subject
PRESCRIPTION STYLE  
dc.subject
QUALITY OF CARE  
dc.subject
TREATMENT GOALS ATTAINMENT  
dc.subject.classification
Políticas y Servicios de Salud  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2020-11-20T17:15:21Z  
dc.journal.volume
153  
dc.journal.pagination
86-92  
dc.journal.pais
Irlanda  
dc.description.fil
Fil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Endocrinología Experimental y Aplicada. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Centro de Endocrinología Experimental y Aplicada; Argentina  
dc.description.fil
Fil: Elgart, Jorge Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Endocrinología Experimental y Aplicada. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Centro de Endocrinología Experimental y Aplicada; Argentina  
dc.description.fil
Fil: Forti, Luján. Sanofi Aventis Argentina Sociedad Anonima.; Argentina  
dc.description.fil
Fil: Querzoli, Ivanna. Sanofi Aventis Argentina Sociedad Anonima.; Argentina  
dc.description.fil
Fil: Chantelot, Jean Marc. Sanofi; Francia  
dc.journal.title
Diabetes Research and Clinical Practice  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.diabres.2019.05.008  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(18)31768-6/fulltext